Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Pemetrexed/PD:

Search results

Items: 1 to 20 of 256

1.

Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo.

Tatsuta T, Satoh T, Sugawara S, Hara A, Hosono M.

PLoS One. 2018 Jan 3;13(1):e0190653. doi: 10.1371/journal.pone.0190653. eCollection 2018.

2.

[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].

Qin YY, Zhang DH, Lin XQ, Ouyang M, Zhang JX, Xie ZH, Liu YQ, Li SY, Zhou CZ.

Zhonghua Zhong Liu Za Zhi. 2017 Nov 23;39(11):855-861. doi: 10.3760/cma.j.issn.0253-3766.2017.11.009. Chinese.

PMID:
29151293
3.

Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells.

Küçüktürkmen B, Bozkır A.

Drug Dev Ind Pharm. 2018 Feb;44(2):306-315. doi: 10.1080/03639045.2017.1391835. Epub 2017 Nov 2.

PMID:
29023168
4.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
5.

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC.

J Clin Oncol. 2017 Dec 20;35(36):4027-4034. doi: 10.1200/JCO.2017.73.9250. Epub 2017 Oct 2.

PMID:
28968167
6.

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.

Greystoke A, Steele N, Arkenau HT, Blackhall F, Md Haris N, Lindsay CR, Califano R, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E.

Br J Cancer. 2017 Sep 26;117(7):938-946. doi: 10.1038/bjc.2017.271. Epub 2017 Aug 24.

7.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G.

J Clin Oncol. 2017 Nov 1;35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012. Epub 2017 Sep 11.

PMID:
28892431
8.

Development of a Prodrug of Levofloxacin to Avoid Chelation with Al3+ and of Pemetrexed Dimedoxomil Esters for Oral Administration.

Matsuyama K.

Yakugaku Zasshi. 2017;137(9):1087-1094. doi: 10.1248/yakushi.17-00095. Review. Japanese.

9.

c-FLIP and the NOXA/Mcl-1 axis participate in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells.

Zhao X, Kong F, Wang L, Zhang H.

PLoS One. 2017 Sep 1;12(9):e0184135. doi: 10.1371/journal.pone.0184135. eCollection 2017.

11.

Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.

Facchetti G, Petrella F, Spaggiari L, Rimoldi I.

Eur J Med Chem. 2017 Dec 15;142:266-270. doi: 10.1016/j.ejmech.2017.07.063. Epub 2017 Aug 2. Review.

PMID:
28800871
12.

First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC).

Spigel DR, Mekhail TM, Waterhouse D, Hadley T, Webb C, Burris HA 3rd, Hainsworth JD, Greco FA.

Cancer Invest. 2017 Sep 14;35(8):541-546. doi: 10.1080/07357907.2017.1344698. Epub 2017 Aug 1.

PMID:
28762849
13.

Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.

Szymiczek A, Carbone M, Pastorino S, Napolitano A, Tanji M, Minaai M, Pagano I, Mason JM, Pass HI, Bray MR, Mak TW, Yang H.

Oncogene. 2017 Nov 16;36(46):6501-6507. doi: 10.1038/onc.2017.266. Epub 2017 Jul 31.

14.

Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Zhao XM, Zhao J, Wu XH, Luo ZG, Wang HJ, Yu H, Chang JH, Wang JL.

Cancer Chemother Pharmacol. 2017 Oct;80(4):851-860. doi: 10.1007/s00280-017-3399-1. Epub 2017 Jul 28.

PMID:
28755014
15.

PEMETREXED-INDUCED PSEUDOCELLULITIS - A RARE CUTANEOUS ADVERSE REACTION TO MULTI-TARGETED ANTIFOLATE THERAPY.

Wollina U, Hansel G, Zschuppe E, Tchernev G.

Georgian Med News. 2017 Jun;(267):81-84.

PMID:
28745612
16.
17.

A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.

Xu Y, Huang Z, Gong L, Fan Y.

Anticancer Drugs. 2017 Oct;28(9):1056-1061. doi: 10.1097/CAD.0000000000000540.

18.

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P.

Nat Med. 2017 Aug;23(8):929-937. doi: 10.1038/nm.4369. Epub 2017 Jul 17.

19.

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.

Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S.

Clin Lung Cancer. 2017 Sep;18(5):589-593. doi: 10.1016/j.cllc.2017.03.010. Epub 2017 Mar 22.

PMID:
28690011
20.

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.

Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Cancer Sci. 2017 Sep;108(9):1843-1849. doi: 10.1111/cas.13309. Epub 2017 Jul 26.

Supplemental Content

Loading ...
Support Center